Altrius Capital Management Inc Grows Position in Pfizer Inc. (NYSE:PFE)

Altrius Capital Management Inc lifted its holdings in Pfizer Inc. (NYSE:PFE) by 2.2% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 84,064 shares of the biopharmaceutical company’s stock after purchasing an additional 1,842 shares during the period. Altrius Capital Management Inc’s holdings in Pfizer were worth $3,083,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. RB Capital Management LLC increased its holdings in shares of Pfizer by 6.7% during the 1st quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock worth $282,000 after buying an additional 341 shares during the last quarter. Ironwood Wealth Management LLC. increased its stake in Pfizer by 1.1% during the first quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock worth $1,868,000 after acquiring an additional 400 shares during the last quarter. United Bank lifted its stake in shares of Pfizer by 0.6% in the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after purchasing an additional 290 shares during the last quarter. Ergoteles LLC grew its holdings in shares of Pfizer by 136.3% during the 1st quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock worth $1,903,000 after purchasing an additional 21,209 shares during the period. Finally, Mackenzie Financial Corp increased its position in shares of Pfizer by 6.4% during the 1st quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock worth $69,238,000 after purchasing an additional 79,887 shares during the last quarter. 68.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $75.00 target price on shares of Pfizer in a research note on Monday, October 2nd. Morgan Stanley lowered their price objective on shares of Pfizer from $39.00 to $37.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 1st. UBS Group reissued a “neutral” rating and issued a $34.00 target price (down previously from $36.00) on shares of Pfizer in a research report on Friday, October 20th. Truist Financial lowered their price target on Pfizer from $62.00 to $42.00 and set a “buy” rating for the company in a research report on Tuesday, October 17th. Finally, JPMorgan Chase & Co. cut their price objective on Pfizer from $36.00 to $34.00 and set a “neutral” rating on the stock in a report on Monday, October 16th. Twelve equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $42.50.

Pfizer Stock Down 0.0 %

NYSE:PFE traded down $0.01 during mid-day trading on Monday, hitting $29.91. The stock had a trading volume of 7,009,113 shares, compared to its average volume of 25,462,936. Pfizer Inc. has a twelve month low of $28.93 and a twelve month high of $54.93. The stock has a 50-day simple moving average of $31.97 and a two-hundred day simple moving average of $35.23. The company has a current ratio of 2.38, a quick ratio of 2.05 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $168.88 billion, a PE ratio of 16.35, a PEG ratio of 1.91 and a beta of 0.63.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.15. Pfizer had a net margin of 15.30% and a return on equity of 16.72%. The business had revenue of $13.23 billion during the quarter, compared to analysts’ expectations of $13.77 billion. On average, equities research analysts anticipate that Pfizer Inc. will post 1.56 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 4th. Investors of record on Friday, November 10th will be given a $0.41 dividend. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $1.64 dividend on an annualized basis and a yield of 5.48%. Pfizer’s dividend payout ratio (DPR) is presently 89.62%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.